Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
Journal of Hematology & Oncology|October 8, 2017
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cellsFrancesca Megiorni, Giovanni Luca Gravina, Simona Camero, et al.
BMC Cancer|July 8, 2024
Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcomaSimona Camero, Luisa Milazzo, Francesca Vulcano, et al.
International Journal of Radiation Biology|March 10, 2020
Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiationFrancesco Petragnano, Ilaria Pietrantoni, Valentina Di Nisio, et al.
Frontiers in Oncology|January 13, 2022
Deep Seated Tumour Treatments With Electrons of High Energy Delivered at FLASH Rates: The Example of Prostate CancerAlessio Sarti, Patrizia De Maria, Giuseppe Battistoni, et al.
Journal of Contemporary Brachytherapy|April 26, 2021
Adjuvant vaginal interventional radiotherapy in early-stage non-endometrioid carcinoma of corpus uteri: a systematic reviewFrancesca De Felice, Valentina Lancellotta, Lisa Vicenzi, et al.
Frontiers in Pharmacology|December 19, 2022
The botanical drug PBI-05204, a supercritical CO<sub>2</sub> extract of <i>Nerium oleander</i>, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy <i>in vitro</i> and <i>in vivo</i>Sara Vaccaro, Alessandra Rossetti, Antonella Porrazzo, et al.
Frontiers in Oncology|May 16, 2022
MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling SuppressionClara Perrone, Silvia Pomella, Matteo Cassandri, et al.
Cell Death & Disease|June 1, 2026
Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivoMatteo Cassandri, Antonella Porrazzo, Simona Camero, et al.
Cell Death Discovery|November 3, 2025
Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcomaFrancesca Antonella Aiello, Lucrezia D'Archivio, Marika Attili, et al.
International Journal of Radiation Biology|March 4, 2025
Significant interruptions in radiotherapy during curative treatment for prostate cancer are correlated with poorer oncological outcomesMiriam Tomaciello, Antonio Sciurti, Luisa Caprara, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Journal of Hematology & Oncology|October 8, 2017
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cellsFrancesca Megiorni, Giovanni Luca Gravina, Simona Camero, et al.
BMC Cancer|July 8, 2024
Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcomaSimona Camero, Luisa Milazzo, Francesca Vulcano, et al.
International Journal of Radiation Biology|March 10, 2020
Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiationFrancesco Petragnano, Ilaria Pietrantoni, Valentina Di Nisio, et al.
Frontiers in Oncology|January 13, 2022
Deep Seated Tumour Treatments With Electrons of High Energy Delivered at FLASH Rates: The Example of Prostate CancerAlessio Sarti, Patrizia De Maria, Giuseppe Battistoni, et al.
Journal of Contemporary Brachytherapy|April 26, 2021
Adjuvant vaginal interventional radiotherapy in early-stage non-endometrioid carcinoma of corpus uteri: a systematic reviewFrancesca De Felice, Valentina Lancellotta, Lisa Vicenzi, et al.
Frontiers in Pharmacology|December 19, 2022
The botanical drug PBI-05204, a supercritical CO<sub>2</sub> extract of <i>Nerium oleander</i>, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy <i>in vitro</i> and <i>in vivo</i>Sara Vaccaro, Alessandra Rossetti, Antonella Porrazzo, et al.
Frontiers in Oncology|May 16, 2022
MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling SuppressionClara Perrone, Silvia Pomella, Matteo Cassandri, et al.
Cell Death & Disease|June 1, 2026
Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivoMatteo Cassandri, Antonella Porrazzo, Simona Camero, et al.
Cell Death Discovery|November 3, 2025
Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcomaFrancesca Antonella Aiello, Lucrezia D'Archivio, Marika Attili, et al.
International Journal of Radiation Biology|March 4, 2025
Significant interruptions in radiotherapy during curative treatment for prostate cancer are correlated with poorer oncological outcomesMiriam Tomaciello, Antonio Sciurti, Luisa Caprara, et al.
Pageof 16